Zhongguancun: Subsidiary Company's Application for Market Approval of Metoprolol Tartrate Injection Accepted

Announcement from Zhongguancun: Beijing Huasu Pharmaceutical Co., Ltd., a subsidiary company, recently received a "Notice of Acceptance" issued by the National Medical Products Administration. The application for market approval of Propranolol Hydrochloride Injection has been accepted. This medication is clinically used to treat angina, premature contractions, paroxysmal tachycardia, etc. Beijing Huasu is the 17th domestic company to submit an application for market approval of this generic drug.